Circulating tumor cell analysis in metastatic triple-negative breast cancers

Mark Jesus M Magbanua, Lisa A. Carey, Amy DeLuca, Jimmy Hwang, Janet H. Scott, Mothaffar F. Rimawi, Erica L. Mayer, P. Kelly Marcom, Minetta C Liu, Francisco J. Esteva, John W. Park, Hope S. Rugo

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Purpose: Recent developments in rare-cell technology have led to improved blood-based assays that allow for the reliable detection, enumeration, and more recently, genomic profiling of circulating tumor cells (CTC). We evaluated two different approaches for enumeration of CTCs in a prospective therapeutic study of patients with metastatic triple-negative breast cancer (TNBC). Experimental Design: The CellSearch system, a commercially available and U.S. Food and Drug Administration (FDA)-cleared assay for CTC enumeration, and IE/FC, an alternative method using EPCAM-based immunomagnetic enrichment and flow cytometry that maintains cell viability, were used to enumerate CTCs in the blood of patients with metastatic TNBC. CTC numbers were assessed at baseline and 7 to 14 days after initiation of therapy with cetuximab-carboplatin in a phase II multicenter clinical trial (TBCRC 001). Results: CTC numbers from two methods were significantly correlated at baseline (r =0.62) and at 7 to 14 days (r =0.53). Baseline CTCs showed no association with time-to-progression (TTP), whereas CTCs at 7 to 14 days were significantly correlated with TTP (CellSearch P =0.02; IE/FC P =0.03). CTCs at both time points were significantly associated with overall survival (OS) [CellSearch: baseline (P =0.0001) and 7 to 14 days (P < 0.0001); IE/FC: baseline (P =0.0009) and 7 to 14 days (P =0.0086)]. Conclusions: Our findings demonstrate that CTC enumeration by two different assays was highly concordant. In addition, results of both assays were significantly correlated with TTP and OS in patients with TNBC. The IE/FC method is also easily adapted to isolation of pure populations of CTCs for genomic profiling. Clin Cancer Res; 21(5); 1098-105.

Original languageEnglish (US)
Pages (from-to)1098-1105
Number of pages8
JournalClinical Cancer Research
Volume21
Issue number5
DOIs
StatePublished - Mar 1 2015
Externally publishedYes

Fingerprint

Triple Negative Breast Neoplasms
Circulating Neoplastic Cells
Cell Count
Metagenomics
Phase II Clinical Trials
Survival
Carboplatin
United States Food and Drug Administration
Multicenter Studies
Cell Survival
Flow Cytometry
Research Design
Prospective Studies
Technology
Therapeutics
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Magbanua, M. J. M., Carey, L. A., DeLuca, A., Hwang, J., Scott, J. H., Rimawi, M. F., ... Rugo, H. S. (2015). Circulating tumor cell analysis in metastatic triple-negative breast cancers. Clinical Cancer Research, 21(5), 1098-1105. https://doi.org/10.1158/1078-0432.CCR-14-1948

Circulating tumor cell analysis in metastatic triple-negative breast cancers. / Magbanua, Mark Jesus M; Carey, Lisa A.; DeLuca, Amy; Hwang, Jimmy; Scott, Janet H.; Rimawi, Mothaffar F.; Mayer, Erica L.; Marcom, P. Kelly; Liu, Minetta C; Esteva, Francisco J.; Park, John W.; Rugo, Hope S.

In: Clinical Cancer Research, Vol. 21, No. 5, 01.03.2015, p. 1098-1105.

Research output: Contribution to journalArticle

Magbanua, MJM, Carey, LA, DeLuca, A, Hwang, J, Scott, JH, Rimawi, MF, Mayer, EL, Marcom, PK, Liu, MC, Esteva, FJ, Park, JW & Rugo, HS 2015, 'Circulating tumor cell analysis in metastatic triple-negative breast cancers', Clinical Cancer Research, vol. 21, no. 5, pp. 1098-1105. https://doi.org/10.1158/1078-0432.CCR-14-1948
Magbanua MJM, Carey LA, DeLuca A, Hwang J, Scott JH, Rimawi MF et al. Circulating tumor cell analysis in metastatic triple-negative breast cancers. Clinical Cancer Research. 2015 Mar 1;21(5):1098-1105. https://doi.org/10.1158/1078-0432.CCR-14-1948
Magbanua, Mark Jesus M ; Carey, Lisa A. ; DeLuca, Amy ; Hwang, Jimmy ; Scott, Janet H. ; Rimawi, Mothaffar F. ; Mayer, Erica L. ; Marcom, P. Kelly ; Liu, Minetta C ; Esteva, Francisco J. ; Park, John W. ; Rugo, Hope S. / Circulating tumor cell analysis in metastatic triple-negative breast cancers. In: Clinical Cancer Research. 2015 ; Vol. 21, No. 5. pp. 1098-1105.
@article{25b0fcd7f8a74c2eaa6ec3091fee488e,
title = "Circulating tumor cell analysis in metastatic triple-negative breast cancers",
abstract = "Purpose: Recent developments in rare-cell technology have led to improved blood-based assays that allow for the reliable detection, enumeration, and more recently, genomic profiling of circulating tumor cells (CTC). We evaluated two different approaches for enumeration of CTCs in a prospective therapeutic study of patients with metastatic triple-negative breast cancer (TNBC). Experimental Design: The CellSearch system, a commercially available and U.S. Food and Drug Administration (FDA)-cleared assay for CTC enumeration, and IE/FC, an alternative method using EPCAM-based immunomagnetic enrichment and flow cytometry that maintains cell viability, were used to enumerate CTCs in the blood of patients with metastatic TNBC. CTC numbers were assessed at baseline and 7 to 14 days after initiation of therapy with cetuximab-carboplatin in a phase II multicenter clinical trial (TBCRC 001). Results: CTC numbers from two methods were significantly correlated at baseline (r =0.62) and at 7 to 14 days (r =0.53). Baseline CTCs showed no association with time-to-progression (TTP), whereas CTCs at 7 to 14 days were significantly correlated with TTP (CellSearch P =0.02; IE/FC P =0.03). CTCs at both time points were significantly associated with overall survival (OS) [CellSearch: baseline (P =0.0001) and 7 to 14 days (P < 0.0001); IE/FC: baseline (P =0.0009) and 7 to 14 days (P =0.0086)]. Conclusions: Our findings demonstrate that CTC enumeration by two different assays was highly concordant. In addition, results of both assays were significantly correlated with TTP and OS in patients with TNBC. The IE/FC method is also easily adapted to isolation of pure populations of CTCs for genomic profiling. Clin Cancer Res; 21(5); 1098-105.",
author = "Magbanua, {Mark Jesus M} and Carey, {Lisa A.} and Amy DeLuca and Jimmy Hwang and Scott, {Janet H.} and Rimawi, {Mothaffar F.} and Mayer, {Erica L.} and Marcom, {P. Kelly} and Liu, {Minetta C} and Esteva, {Francisco J.} and Park, {John W.} and Rugo, {Hope S.}",
year = "2015",
month = "3",
day = "1",
doi = "10.1158/1078-0432.CCR-14-1948",
language = "English (US)",
volume = "21",
pages = "1098--1105",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "5",

}

TY - JOUR

T1 - Circulating tumor cell analysis in metastatic triple-negative breast cancers

AU - Magbanua, Mark Jesus M

AU - Carey, Lisa A.

AU - DeLuca, Amy

AU - Hwang, Jimmy

AU - Scott, Janet H.

AU - Rimawi, Mothaffar F.

AU - Mayer, Erica L.

AU - Marcom, P. Kelly

AU - Liu, Minetta C

AU - Esteva, Francisco J.

AU - Park, John W.

AU - Rugo, Hope S.

PY - 2015/3/1

Y1 - 2015/3/1

N2 - Purpose: Recent developments in rare-cell technology have led to improved blood-based assays that allow for the reliable detection, enumeration, and more recently, genomic profiling of circulating tumor cells (CTC). We evaluated two different approaches for enumeration of CTCs in a prospective therapeutic study of patients with metastatic triple-negative breast cancer (TNBC). Experimental Design: The CellSearch system, a commercially available and U.S. Food and Drug Administration (FDA)-cleared assay for CTC enumeration, and IE/FC, an alternative method using EPCAM-based immunomagnetic enrichment and flow cytometry that maintains cell viability, were used to enumerate CTCs in the blood of patients with metastatic TNBC. CTC numbers were assessed at baseline and 7 to 14 days after initiation of therapy with cetuximab-carboplatin in a phase II multicenter clinical trial (TBCRC 001). Results: CTC numbers from two methods were significantly correlated at baseline (r =0.62) and at 7 to 14 days (r =0.53). Baseline CTCs showed no association with time-to-progression (TTP), whereas CTCs at 7 to 14 days were significantly correlated with TTP (CellSearch P =0.02; IE/FC P =0.03). CTCs at both time points were significantly associated with overall survival (OS) [CellSearch: baseline (P =0.0001) and 7 to 14 days (P < 0.0001); IE/FC: baseline (P =0.0009) and 7 to 14 days (P =0.0086)]. Conclusions: Our findings demonstrate that CTC enumeration by two different assays was highly concordant. In addition, results of both assays were significantly correlated with TTP and OS in patients with TNBC. The IE/FC method is also easily adapted to isolation of pure populations of CTCs for genomic profiling. Clin Cancer Res; 21(5); 1098-105.

AB - Purpose: Recent developments in rare-cell technology have led to improved blood-based assays that allow for the reliable detection, enumeration, and more recently, genomic profiling of circulating tumor cells (CTC). We evaluated two different approaches for enumeration of CTCs in a prospective therapeutic study of patients with metastatic triple-negative breast cancer (TNBC). Experimental Design: The CellSearch system, a commercially available and U.S. Food and Drug Administration (FDA)-cleared assay for CTC enumeration, and IE/FC, an alternative method using EPCAM-based immunomagnetic enrichment and flow cytometry that maintains cell viability, were used to enumerate CTCs in the blood of patients with metastatic TNBC. CTC numbers were assessed at baseline and 7 to 14 days after initiation of therapy with cetuximab-carboplatin in a phase II multicenter clinical trial (TBCRC 001). Results: CTC numbers from two methods were significantly correlated at baseline (r =0.62) and at 7 to 14 days (r =0.53). Baseline CTCs showed no association with time-to-progression (TTP), whereas CTCs at 7 to 14 days were significantly correlated with TTP (CellSearch P =0.02; IE/FC P =0.03). CTCs at both time points were significantly associated with overall survival (OS) [CellSearch: baseline (P =0.0001) and 7 to 14 days (P < 0.0001); IE/FC: baseline (P =0.0009) and 7 to 14 days (P =0.0086)]. Conclusions: Our findings demonstrate that CTC enumeration by two different assays was highly concordant. In addition, results of both assays were significantly correlated with TTP and OS in patients with TNBC. The IE/FC method is also easily adapted to isolation of pure populations of CTCs for genomic profiling. Clin Cancer Res; 21(5); 1098-105.

UR - http://www.scopus.com/inward/record.url?scp=84927728470&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927728470&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-14-1948

DO - 10.1158/1078-0432.CCR-14-1948

M3 - Article

C2 - 25524311

AN - SCOPUS:84927728470

VL - 21

SP - 1098

EP - 1105

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 5

ER -